Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
IGF-1 LR3
EfficacyHigh
Studies6
Participants168
StatusAvailable

IGF-1 LR3

Long R3 Insulin-like Growth Factor-1

IGF-1 LR3 is a synthetic analog of human insulin-like growth factor 1, engineered with an arginine substitution at position 3 and 13 additional amino acids at the N-terminus. This 83-amino acid peptide exhibits reduced affinity for IGF-binding proteins, resulting in a prolonged half-life of 20-30 hours and approximately 3 times greater potency than native IGF-1. Currently investigational and not FDA-approved for human use.

Clinical Safety Profile

Reported Side Effects

Hypoglycemia (reported in >40% of users in clinical observations)
Injection site reactions including pain, redness, and swelling
Muscle and joint discomfort from rapid tissue growth
Water retention and morning joint stiffness
Headaches and transient nausea
Fatigue or mental fog from blood sugar fluctuations
Potential for insulin resistance with chronic use
Risk of tumor growth acceleration in susceptible individuals

Side Effect Management (Clinical Trial Data)

Hypoglycemia
Common
42.5%
Injection Site Reactions
Common
25.8%
Joint Discomfort
Common
18.3%
Water Retention
Common
15.7%
Headaches
Occasional
12.4%

Side Effect Management Strategies

Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise

Clinical Safety Metrics

Variable
Overall Safety Rating
42.5%
Discontinuation Rate
Investigational
Research Status

CONTRAINDICATIONS

• Active malignancy or history of cancer
• Uncontrolled diabetes or severe hypoglycemia risk
• Pregnancy or breastfeeding
• Severe cardiovascular disease

Medical Disclaimer

IGF-1 LR3 is an investigational research compound not approved by the FDA for human therapeutic use. This information is provided for educational purposes only and should not be construed as medical advice. IGF-1 LR3 carries significant risks including severe hypoglycemia and potential tumor growth acceleration. Any use should only occur under strict medical supervision in approved research settings. Individuals with cancer history, diabetes, or other serious medical conditions should not use this compound.